Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robin Kramer is Director at Biogen. OQRO lists 11 transactions filed with the SEC under this name, the latest on Mar 12, 2026, each linked to the official Form 4.
Director
Disclosures on record
11
Companies involved
2
As of the latest filing on , Robin Kramer reported holding 11,472 shares of Biogen (BIIB), worth about $2.88M at the last close of $251 (Nov 18, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Biogen BIIB | 11,472 | 11K direct | $251 | $2.88M | Feb 6, 2026 |
Is this Robin Kramer’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Mar 9, 202626Kdisclosed Mar 12
DetailsOfficial recordBiogenBIIB
10 disclosures · Feb 2026
Feb 13, 20268,450disclosed Feb 18
Feb 6, 2026703disclosed Feb 10
DetailsOfficial recordFeb 6, 20263,511disclosed Feb 10
DetailsOfficial recordFeb 6, 2026789disclosed Feb 10
DetailsOfficial recordFeb 6, 20263,511disclosed Feb 10
DetailsOfficial recordFeb 6, 2026789disclosed Feb 10
DetailsOfficial recordFeb 6, 2026703disclosed Feb 10
DetailsOfficial recordFeb 6, 2026207disclosed Feb 10
DetailsOfficial recordFeb 6, 2026273disclosed Feb 10
DetailsOfficial recordFeb 6, 20261,063disclosed Feb 10
DetailsOfficial recordRobin Kramer has no open-market purchase on record since 2017. Sales in 2 of the 10 years since 2017.
Robin Kramer reported 0 open-market purchases and 2 sales since 2017; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2018 | — | $107K1×1 trade |
| 2017 | — | $76K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Feb 6, 2026, Robin Kramer reported holding 11,472 shares of Biogen (BIIB). At the last close of $251 on Nov 18, 2026, that is about $2.88M. This is the stake disclosed in filings, not a net worth.
No public filing gives Robin Kramer's net worth. What SEC Form 4 shows is the stock stake: 11,472 shares of Biogen (BIIB), about $2.88M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Robin Kramer has no open-market purchase on record since 2017. Sales in 2 of the 10 years since 2017.
In SEC filings since 2017: no open-market purchase is on record; the latest open-market sale is from 2018.
Hertz Global Holdings (HTZ), from 2017 to 2018: 0 purchases and 2 sales.
Robin Kramer reported 0 open-market purchases and 2 sales here, 2017 to 2018.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.